Name: MLN4924 (Pevonedistat)
Brand: Selleck Chemicals
SKU: S7109
Availability: InStock
Rating: 5 (148 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Proteasome E3 Ligase DUB p97 SUMO E2 conjugating
Other E1 Activating Inhibitors	TAK-243 (MLN7243) PYR-41 ML792 TAS4464 COH000 DKM 2-93 Pevonedistat hydrochloride PYZD-4409 NEDD8 inhibitor M22

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
K562	Antiproliferative assay	72 hrs	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay, EC50 = 0.108 μM.	24900352
U2OS	Antitumor assay	72 hrs	Antitumor activity against human U2OS cells after 72 hrs by MTT assay, IC50 = 0.16 μM.	28388520
HCT116	Antitumor assay	72 hrs	Antitumor activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 0.19 μM.	28388520
Caco2	Function assay	16 hrs	Inhibition of NAE-mediated Ubcl2-NEDD8 conjugation in human Caco2 cells after 16 hrs by Western blot analysis, EC50 = 3.4 μM.	29232579
Caco2	Function assay	16 hrs	Inhibition of NAE-mediated Ubcl2-NEDD8 conjugation in human Caco2 cells after 16 hrs by Western blot analysis, EC50 = 3.4 μM.	29232579
Caco2	Cytotoxicity assay	72 hrs	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay, IC50 = 4.4 μM.	29232579
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 89 mg/mL (200.66 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 22 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5% DMSO 1 30% PEG 300 2 5% Tween 80 3 ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.000mg/ml (9.02mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 50 μL Tween-80 to the above system, mix evenly to clarify it; Then continue to add 600 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	443.52	Formula	C₂₁H₂₅N₅O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	905579-51-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Features	A mechanism-based inhibitor of NAE, and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme.
Targets/IC₅₀/Ki	NAE (Cell-free assay) 4 nM
In vitro	Pevonedistat (MLN4924) is structurally related to adenosine 59-monophosphate (AMP)—a tight binding product of the NAE reaction. It (3 μM) selectively inhibits NAE in HCT-116 cell lysates and inhibits overall protein turnover by <9% in HCT-116 cells. This compound results in a dose-dependent decrease of Ubc12–NEDD8 thioester and NEDD8–cullin conjugates with an IC50 < 0.1 μM in HCT-116 cells, resulting in a reciprocal increase in the abundance of the known CRL substrates CDT1, p27 and NRF2, but not non-CRL substrates. It (3 μM) leads cells to accumulate in S-phase as early as 8 hours and results in a significant fraction of cells contained 4N DNA content by 24 hours in HCT-116 cells. At the same concentration, it results in rapid accumulation of pIkappaBalpha, decrease in nuclear p65 content, reduction of nuclear factor-kappaB (NF-kappaB) transcriptional activity, and G(1) arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-kappaB pathway inhibition in ABC DLBCL cells. At 1 μM, it triggers DNA replication and inhibits cell proliferation by stabilizing the DNA replication factor Cdt1, a substrate of cullins 1 and 4. This concentration, which is sufficient to elevate Cdt1 for 4-5 hours, is found to be sufficient to induce DNA replication and to activate apoptosis and senescence pathways. Treatment with this compound induces the characteristics of senescence phenotypes as evidenced by enlarged and flattened cellular morphology and positive staining of senescence-associated β-Gal. MLN4924-induced senescence is associated with cellular response to DNA damage, triggered by accumulation of DNA-licensing proteins CDT1 and ORC1, as a result of inactivation of CRL/SCF E3s. It is irreversible and coupled with persistent accumulation of p21 and sustained activation of DNA damage response.
Kinase Assay	In vitro E1-activating enzyme assays
Kinase Assay	A time-resolved fluorescence energy transfer assay format is used to measure the in vitro activity of NAE. The enzymatic reaction, containing 50 μL 50 mM HEPES, pH 7.5, 0.05% BSA, 5 mM MgCl₂, 20 μM ATP, 250 μM glutathione, 10 nM Ubc12–GST, 75 nM NEDD8–Flag and 0.3 nM recombinant human NAE enzyme, is incubated at 24 ℃ for 90 min in a 384-well plate, before termination with 25 μL of stop/detection buffer (0.1 M HEPES, pH 7.5, 0.05% Tween20, 20 mM EDTA, 410 mM KF, 0.53 nM Europium-Cryptate-labelled monoclonal Flag-M2-specific antibody and 8.125 μg/mL PHYCOLINK allophycocyanin (XL-APC)-labelled GST-specific antibody. After incubation for 2 hours at 24 ℃, the plate is read on the LJL Analyst HT Multi-Mode instrument using a time-resolved fluorescence method. A similar assay protocol is used to measure other E1 enzymes.
In vivo	Pevonedistat (MLN4924) (60 mg/kg) results in a dose- and time-dependent decrease of NEDD8–cullin levels as early as 30 min after administration in HCT-116 tumour-bearing mice, with maximal effect 1–2 hours post-dose. It also leads to a dose- and time-dependent increase in the steady state levels of NRF2 and CDT1 in HCT-116 tumour-bearing mice. This compound leads to DNA damage in the tumour indicated by the increased levels of phosphorylated CHK1 in HCT-116 tumour-bearing mice. When administered on a BID schedule at 30 mg/kg and 60 mg/kg, it inhibits tumour growth with T/C values of 0.36 and 0.15, respectively, in mice bearing HCT-116 xenografts. It (60 mg/kg) blocks NAE pathway biomarkers and results in complete tumor growth inhibition in mice bearing human xenograft tumors of ABC- and GCB-DLBCL. This compound (60 mg/kg) results in NF-kappaB pathway inhibition accompanied by tumor regressions in primary human tumor mice models of ABC-DLBCL.
References	[1] https://pubmed.ncbi.nlm.nih.gov/19360080/ [2] https://pubmed.ncbi.nlm.nih.gov/20525923/ [3] https://pubmed.ncbi.nlm.nih.gov/21159650/ [4] https://pubmed.ncbi.nlm.nih.gov/21677879/

Applications

Methods	Biomarkers	PMID
Western blot	Culin 3 / CDT2 / CDT1 / SET8 / p21 / p-p53 / p-CHK1 / p-CHK2 / CHK2 / γH2AX / H2AX / PARP / c-PARP Culin 1 / WEE1 / p27 / p-H3 / cyclin B1 Cleaved caspase-3 / Cleaved PARP pro-apoptotic and anti-apoptotic proteins p-c-Jun / c-Jun p-H2A / p-CHK2 p-AKT / p-mTOR / p-70S6K	28838998
Immunofluorescence	RhoB / VE-cadherin / F-actin	29358211
Growth inhibition assay	Cell viability	27333051

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04985656	Withdrawn	Myelodysplastic Syndromes (MDS)	Takeda	October 1 2021	Phase 2
NCT04800627	Terminated	Locally Advanced Malignant Solid Neoplasm\|Metastatic Malignant Solid Neoplasm\|Unresectable Malignant Solid Neoplasm	M.D. Anderson Cancer Center	March 29 2021	Phase 1\|Phase 2
NCT04266795	Active not recruiting	Acute Myeloid Leukemia (AML)	Takeda	October 13 2020	Phase 2
NCT03770260	Completed	Recurrent Multiple Myeloma\|Refractory Multiple Myeloma	National Cancer Institute (NCI)	February 10 2020	Phase 1
NCT04172844	Active not recruiting	Acute Myelogenous Leukemia	Medical College of Wisconsin	January 13 2020	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

MLN4924 (Pevonedistat) NAE inhibitor

Chemical Structure

Molecular Weight: 443.52